Publication list - Publika - Scientific publications from Oslo University Hospital

Publications by Jon Magnus Tangen

46 publications found

Original articles

Fagerhol MK, Johnson E, Tangen JM, Hollan I, Mirlashari MR, Nissen-Meyer LSH, Hetland G (2020)
NETs analysed by novel calprotectin-based assays in blood donors and patients with multiple myeloma or rheumatoid arthritis: A pilot study
Scand J Immunol, 91 (5), e12870
DOI 10.1111/sji.12870, PubMed 32034957

Tangen JM, Tjønnfjord GE, Gulbrandsen N, Gedde-Dahl T, Stormorken E, Anderson K, Vo CD, Schjesvold FH, For Oslo Myeloma Center (2018)
Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis
BMC Cancer, 18 (1), 801
DOI 10.1186/s12885-018-4722-x, PubMed 30089450

Tangen JM, Holien T, Mirlashari MR, Misund K, Hetland G (2017)
Cytotoxic Effect on Human Myeloma Cells and Leukemic Cells by the Agaricus blazei Murill Based Mushroom Extract, Andosan™
Biomed Res Int, 2017, 2059825
DOI 10.1155/2017/2059825, PubMed 29238712

Hetland G, Eide DM, Tangen JM, Haugen MH, Mirlashari MR, Paulsen JE (2016)
The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse
PLoS One, 11 (12), e0167754
DOI 10.1371/journal.pone.0167754, PubMed 28002446

Tangen JM, Tierens A, Caers J, Binsfeld M, Olstad OK, Trøseid AM, Wang J, Tjønnfjord GE, Hetland G (2015)
Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study
Biomed Res Int, 2015, 718539
DOI 10.1155/2015/718539, PubMed 25664323

Akkök ÇA, Bergrem A, Tangen JM (2014)
Hyperleukocytosis
Tidsskr Nor Laegeforen, 134 (14), 1365
DOI 10.4045/tidsskr.13.1559, PubMed 25096431

Tangen JM, Jaworska A (2013)
Treatment of acute radiation injuries
Tidsskr Nor Laegeforen, 133 (20), 2164-6
DOI 10.4045/tidsskr.13.0218, PubMed 24172631

Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V, Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, Kvaløy S (2013)
High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment
Tidsskr Nor Laegeforen, 133 (16), 1735-9
DOI 10.4045/tidsskr.13.0319, PubMed 24005713

Tangen JM, Jaworska A, Mattsson H (2011)
The Fukushima accident--health consequences
Tidsskr Nor Laegeforen, 131 (23), 2342-3
DOI 10.4045/tidsskr.11.0957, PubMed 22139113

Tangen JM, Fløisand Y, Haukås E, Naess IA, Skjelbakken T, Stapnes C, Tjønnfjord GE (2010)
[Survival in adults with acute lymphoblastic leukaemia]
Tidsskr Nor Laegeforen, 130 (17), 1710-3
DOI 10.4045/tidsskr.09.1293, PubMed 20835280

Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E (2010)
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
Br J Haematol, 150 (3), 293-302
DOI 10.1111/j.1365-2141.2010.08235.x, PubMed 20497178

Akkök CA, Holte MR, Tangen JM, Ostenstad B, Bruserud O (2008)
Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells
Transfusion, 49 (2), 354-61
DOI 10.1111/j.1537-2995.2008.01949.x, PubMed 18980622

Iversen PO, Ukrainchenko E, Afanasyev B, Hulbekkmo K, Choukah A, Gulbrandsen N, Wisløff F, Tangen JM (2008)
Impaired nutritional status during intensive chemotherapy in Russian and Norwegian cohorts with acute myeloid leukemia
Leuk Lymphoma, 49 (10), 1916-24
DOI 10.1080/10428190802339723, PubMed 18949615

Schjesvold FH, Sjo M, Tangen JM, Hammerstrøm J, Brinch L (2008)
[High-dose treatment of systemic AL-amyloidosis with autologous stem cell support]
Tidsskr Nor Laegeforen, 128 (12), 1392-6
PubMed 18552900

Tangen JM, Fløisand Y, Foss-Abrahamsen J, Haukås E, Naess IA, Skjelbakken T (2008)
[Survival in adults with acute myelogenous leukemia]
Tidsskr Nor Laegeforen, 128 (10), 1164-7
PubMed 18480864

Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G, Tangen JM, Westin J, Nordic Myeloma Study Group (2008)
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
Cancer, 112 (1), 129-35
DOI 10.1002/cncr.23145, PubMed 17973267

Grövdal M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Wallvik J, Tangen JM, Oberg G, Jacobsen SE, Hokland P, Porwit A, Hellström-Lindberg E (2007)
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome
Clin Cancer Res, 13 (23), 7107-12
DOI 10.1158/1078-0432.CCR-07-1193, PubMed 18056190

Torfoss D, Høiby EA, Tangen JM, Holte H, Bø K, Meyer P, Grøttum K, Weyde K, Lauritzsen GF, Sandstad B, Jacobsen AB, Olsen H, Kvaløy S (2007)
Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial
J Antimicrob Chemother, 59 (4), 711-7
DOI 10.1093/jac/dkm003, PubMed 17327294

Lenhoff S, Hjorth M, Westin J, Brinch L, Bäckström B, Carlson K, Christiansen I, Dahl IM, Gimsing P, Hammerström J, Johnsen HE, Juliusson G, Linder O, Mellqvist UH, Nesthus I, Nielsen JL, Tangen JM, Turesson I, Nordic Myeloma Study Group (2006)
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group
Br J Haematol, 133 (4), 389-96
DOI 10.1111/j.1365-2141.2006.06042.x, PubMed 16643445

Broliden PA, Dahl IM, Hast R, Johansson B, Juvonen E, Kjeldsen L, Porwit-MacDonald A, Sjoo M, Tangen JM, Uggla B, Oberg G, Hellstrom-Lindberg E (2006)
Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes
Haematologica, 91 (5), 667-70
PubMed 16670072

Mishra V, Andresen S, Brinch L, Kvaløy S, Ernst P, Lønset MK, Tangen JM, Wikelund J, Flatum C, Baggerød E, Helle B, Vaaler S, Hagen TP (2005)
Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study
Bone Marrow Transplant, 35 (12), 1149-53
DOI 10.1038/sj.bmt.1704988, PubMed 15880133

Sigurdardottir K, Digranes A, Harthug S, Nesthus I, Tangen JM, Dybdahl B, Meyer P, Hopen G, Løkeland T, Grøttum K, Vie W, Langeland N (2005)
A multi-centre prospective study of febrile neutropenia in Norway: microbiological findings and antimicrobial susceptibility
Scand J Infect Dis, 37 (6-7), 455-64
DOI 10.1080/00365540510038497, PubMed 16012006

Hast R, Hellström-Lindberg E, Ohm L, Björkholm M, Celsing F, Dahl IM, Dybedal I, Gahrton G, Lindberg G, Lerner R, Linder O, Löfvenberg E, Nilsson-Ehle H, Paul C, Samuelsson J, Tangen JM, Tidefelt U, Turesson I, Wahlin A, Wallvik J, Winquist I, Oberg G, Bernell P (2003)
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease
Leukemia, 17 (9), 1827-33
DOI 10.1038/sj.leu.2403035, PubMed 12970783

Gruber A, Björkholm M, Brinch L, Evensen S, Gustavsson B, Hedenus M, Juliusson G, Löfvenberg E, Nesthus I, Simonsson B, Sjo M, Stenke L, Tangen JM, Tidefelt U, Udén AM, Paul C, Liliemark J (2003)
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia
Leuk Res, 27 (4), 323-8
DOI 10.1016/s0145-2126(02)00181-9, PubMed 12531223

Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Oberg G, Porwit-MacDonald A, Rådlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F, Scandinavian MDS Group (2003)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life
Br J Haematol, 120 (6), 1037-46
DOI 10.1046/j.1365-2141.2003.04153.x, PubMed 12648074

Wisløff F, Tangen JM, Brinch L, Dahl IM, Gruber FX, Hammerstrøm J, Waage A, Nesthus I, Ernst P (2001)
[High dose therapy with autologous stem cell support--finally a progress in myelomatosis]
Tidsskr Nor Laegeforen, 121 (20), 2402-6
PubMed 11603051

Tangen JM (2000)
[Alexander Pushkin's duel--biographic and medical aspects]
Tidsskr Nor Laegeforen, 120 (10), 1170-2
PubMed 10863347

Lamvik J, Brinch L, Dahl IM, Sjo M, Nesthus I, Tangen JM, Berentsen S, Ly B, Shammas FV (1999)
[Chronic myeloid leukemia in health regions 1, 3, 4 and 5 during the period 1990-96]
Tidsskr Nor Laegeforen, 119 (12), 1733-6
PubMed 10380587

Tangen JM, Berentsen S, Dahl IM, Ly B, Myrvang B (1999)
[Empirical antibiotic treatment of patients with acute myelogenous leukemia]
Tidsskr Nor Laegeforen, 119 (1), 35-8
PubMed 10025202

Hellström-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, Oberg G, Osterborg A, Ost A (1998)
Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients
Blood, 92 (1), 68-75
PubMed 9639501

Tangen JM, Abdelnoor M, Brinch L, Dahl IM, Lamvik J, Ly B, Nesthus I, Wisløff F (1997)
Survival in 86 patients, aged 15-60, with primary acute myelogenous leukemia, treated with a common program in the Norwegian health regions I, III, IV and V in the period 1990-1995
Eur J Haematol, 59 (2), 110-4
DOI 10.1111/j.1600-0609.1997.tb00734.x, PubMed 9293859

Holte H, Kvaløy SO, Engan T, Evensen SA, Mella O, Tangen JM, Wesenberg F, Wist EA (1996)
[High dose therapy with autologous stem cell support in malignant disorders. Excerpt from the statement by the advisory group of the State Health Services]
Tidsskr Nor Laegeforen, 116 (21), 2577-81
PubMed 8928130

Tangen JM, Haaland A (1995)
[Idiopathic hypereosinophilic syndrome. Two patients with multiple organ damage]
Tidsskr Nor Laegeforen, 115 (20), 2535-7
PubMed 7676417

Hellström-Lindberg E, Birgegård G, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Merk K, Tangen JM, Winqvist I (1993)
A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes
Leuk Lymphoma, 11 (3-4), 221-8
DOI 10.3109/10428199309086999, PubMed 7505147

Tangen JM, Wisløff, Andersen OK (1993)
[Immunomodulating treatment of severe aplastic anemia in adults]
Tidsskr Nor Laegeforen, 113 (11), 1351-4
PubMed 8337623

Tangen JM, Abrahamsen AF, Ostenstad B, Bergheim J (1990)
Interleukin-2 receptor levels in non-Hodgkin's lymphoma. Correlation to histological degree of malignancy and presence of constitutional symptoms
Acta Oncol, 29 (5), 581-3
DOI 10.3109/02841869009090055, PubMed 2206570

Tangen JM, Naess A, Aasen T, Morild I (1988)
Non-caseating granulomas in patients with hematologic malignancies. A report of three cases
Acta Med Scand, 223 (1), 83-7
DOI 10.1111/j.0954-6820.1988.tb15769.x, PubMed 3126625

Restan A, Tangen JM, Bergheim J (1987)
[Acute lymphatic leukemia. Acute psychosis during induction treatment]
Tidsskr Nor Laegeforen, 107 (3), 253-4
PubMed 3469781

Tangen JM (1987)
[Disseminated pneumococcal infections in patients with chronic alcoholism]
Tidsskr Nor Laegeforen, 107 (1), 23-4
PubMed 3824284

Tangen JM (1986)
[Wernicke's encephalopathy]
Tidsskr Nor Laegeforen, 106 (23), 1818-9, 1826
PubMed 3764856

Tangen JM (1983)
[Toxoplasmosis and malignant lymphoproliferative disease. A case report]
Tidsskr Nor Laegeforen, 103 (16), 1329-30
PubMed 6688686

Review articles

Hetland G, Tangen JM, Mahmood F, Mirlashari MR, Nissen-Meyer LSH, Nentwich I, Therkelsen SP, Tjønnfjord GE, Johnson E (2020)
Antitumor, Anti-Inflammatory and Antiallergic Effects of Agaricus blazei Mushroom Extract and the Related Medicinal Basidiomycetes Mushrooms, Hericium erinaceus and Grifola frondosa: A Review of Preclinical and Clinical Studies
Nutrients, 12 (5)
DOI 10.3390/nu12051339, PubMed 32397163

Biedron R, Tangen JM, Maresz K, Hetland G (2012)
Agaricus blazei Murill - immunomodulatory properties and health benefits
Funct. Foods Health Dis., 2 (11), 428-447
DOI 10.31989/ffhd.v2i11.72